 |
 |
      |
|
Tree Bark May Fight Lung Cancer: Study
For years, the medical community has derided most holistic and "natural" cures, especially as treatment for deadly diseases like cancer. But now a major medical research center says it's determined how a substance derived from the bark of the South American lapacho tree kills certain kinds of cancer cells. Researchers at UT Southwestern Medical Center in Dallas say their findings also suggest a novel treatment for the most common type of lung cancer. Use of the technique in tests resulted in "a whopping kill" of cancer cells, they said. The researchers say the compound, called beta-lapachone, has shown promising anti-cancer properties and is currently being used in a clinical trial to examine its effectiveness against pancreatic cancer in humans. Until now, however, researchers didn’t know the mechanism of how the compound killed cancer cells. 
In the new study, Boothman and his colleagues in the Simmons Cancer Center found that beta-lapachone interacts with an enzyme called NQO1, which is present at high levels in non-small cell lung cancer and other solid tumors.
In tumors, the compound is metabolized by NQO1 and produces cell death without damaging non-cancerous tissues that do not express this enzyme.
"Basically, we have worked out the mechanism of action of beta-lapachone and devised a way of using that drug for individualized therapy," said Boothman, who is also a professor of pharmacology and radiation oncology.
In healthy cells, NQO1 is either not present or is expressed at low levels. In contrast, certain cancer cells -- like non-small cell lung cancer – over-express the enzyme. Boothman and his colleagues have determined that when beta-lapachone interacts with NQO1, the cell kills itself. Non-small cell lung cancer is the most common type of lung cancer.
Beta-lapachone also disrupts the cancer cell’s ability to repair its DNA, ultimately leading to the cell’s demise. Applying radiation to tumor cells causes DNA damage, which results in a further boost in the amount of NQO1 in the cells. "When you irradiate a tumor, the levels of NQO1 go up," Boothman said. "When you then treat these cells with beta-lapachone, you get synergy between the enzyme and this agent and you get a whopping kill." In the current study, Boothman tested dosing methods on human tumor cells using a synthesized version of beta-lapachone and found that a high dose of the compound given for only two to four hours caused all the NQO1-containing cancer cells to die. Understanding how beta-lapachone works to selectively kill chemotherapy-resistant tumor cells creates a new paradigm for the care of patients with non-small cell lung cancer, the researchers said. They are hoping that by using a drug like beta-lapachone, they can selectively target cancer tumors and kill them more efficiently. The current therapy for non-small cell lung cancer calls for the use of platinum-based drugs in combination with radiation. "Future therapies based on beta-lapachone and NQO1 interaction have the potential to play a major role in treating devastating drug-resistant cancers such as non-small cell lung cancer," said Dr. Erik Bey, lead author of the study and a postdoctoral researcher in the Simmons Cancer Center. "This is the first step in developing chemotherapeutic agents that exploit the proteins needed for a number of cellular processes, such as DNA repair and programmed cell death." About 85% of patients with non-small cell lung cancer have cancer cells containing elevated levels of the NQO1 enzyme, which is produced by a certain gene. Patients who have a different version of the gene would likely not benefit from treatment targeting NQO1, Boothman said. Boothman cautioned that clinical trials of beta-lapachone in lung cancer patients will be needed to determine its effectiveness as a treatment. He and his team have created a simple blood test that would screen patients for the NQO1 enzyme. (Article courtesy of ConsumerAffairs.com)
Email or share this story 
Find with keyword(s): Enter a keyword or phrase to search CaregiversHome's archives for related news topics, the latest news stories, timely times, and reference articles.
Commercial use, redistribution or other forms of reuse of this information is strictly prohibited without the prior written permission of Pederson Publishing.
_____
View The Caregiver's Hotline in which this article first appeared
